Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.
Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs
Jacobson JI
This paper essentially poses the question, “Is it possible to calculate target-specific magnetic resonance energies to restore bio molecular order and inhibit telomerase production under conditions of increasing entropy, even as cells pass M2 checkpoints?” Indeed, a diversity of positive experimental outcomes has pointed to the possibility that non-ionizing radiation (NIR’s) produce positive bio effects of predictable nature. The hypothetical construct is that Pico-Tesla range magnetic fields are physiologic and may possibly affect molecules and molecular assemblies through the piezoelectric effect; most especially due to the supposed quasi-crystalline semi conductive nature of various biological structures. The initial physical mechanism is hypothesized to be photon-phonon transductions, i.e., electro mechanical conversions, via resonance phenomena. Utilizing a novel particle-wave equation, mc2=BvLq, specified magnetic flux densities have been calculated, formulating a possible system of dual resonance. The energy produced by the interaction of the organism and the magnetic field is set equal to the intrinsic energy of a molecule. The outcome of this methodology may possibly provide a new, noninvasive holistic paradigm for adjuvant treatment of cancer. In support of said hypothesis, various experimental outcomes are considered, wherein the given method was utilized to establish magnetic resonance protocols, based on molecular species known to be associated with pathophysiologic conditions including cancer. Thus, if successful, then a possible new adjunctive, non-invasive and non-significant risk approach for telomerase inhibition with conventional cancer therapy is proposed.